Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mildred Iro, a Paediatric Research Fellow working with the Oxford Vaccine Group, won the Lorber Prize for the best paediatric publication of 2017 for her work on childhood encephalitis admissions.

The winning paper, published in Lancet in April 2017, examined trends in hospital admission rates for encephalitis in children over a 33-year period (1979-2011). The results show that while hospital admission rates for all instances of childhood encephalitis in England increased between 1995 and 2011, admissions for mumps encephalitis decreased by 98%, and for measles by 97%, after the introduction of the two-dose MMR vaccination schedule. Mildred’s study is the first to quantify the effect of the MMR vaccine on childhood measles and mumps encephalitis admissions in England. It is also the first to define the incidence of all-cause childhood encephalitis in England.

Mildred Iro joined Oxford University’s Department of Paediatrics in 2012; in 2013 she commenced her DPhil at the Oxford Vaccine Group. She has done most of her paediatric training in Southampton, where she is planning to return after the completion of her doctorate to take up the position of an NIHR Academic Clinical Lecturer in Child Health and Genomics.

The Lorber Prize is given annually by the Royal College of Paediatrics and Child Health. The award honours a pre-consultant grade medical practitioner working in the UK for the best scientific paper related to paediatrics.

 

Similar stories

New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Professor Sue Ann Costa Clemens awarded an Honorary CBE

Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.